The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).
 
Sarmad Sadeghi
Consulting or Advisory Role - Cardiff Oncology (I); Cardinal Health
Research Funding - Merck; Pfizer
 
Imran Siddiqi
Stock and Other Ownership Interests - Allogene Therapeutics; crispr therapeutics; Inovio Pharmaceuticals; Moderna Therapeutics; Moderna Therapeutics
Consulting or Advisory Role - EUSA Pharma
 
Karam Ashouri
No Relationships to Disclose
 
Denice D. Tsao-Wei
No Relationships to Disclose
 
Jon P Cogan
Employment - Vasgene Therapeutics
 
Alexandra Jackovich
No Relationships to Disclose
 
Krithika Chennapan
No Relationships to Disclose
 
Dory Freeman
No Relationships to Disclose
 
Jillian O'Toole
No Relationships to Disclose
 
Adrie van Bokhoven
No Relationships to Disclose
 
Kathleen Torkko
No Relationships to Disclose
 
Inderbir Gill
No Relationships to Disclose
 
Parkash S. Gill
Stock and Other Ownership Interests - Vasgene Therapeutics
 
Thomas W. Flaig
Leadership - Aurora Oncology; University of Colorado/UC Health
Stock and Other Ownership Interests - Aurora Oncology
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
Guru P. Sonpavde
Employment - Myriad Genetics (I)
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; Bicycle Therapeutics; Bristol-Myers Squibb; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Lucence; Merck; Pfizer; Scholar Rock; Seagen; Syapse; Vial
Speakers' Bureau - Exelixis; Gilead Sciences; INFORMAÇÃO BRASILEIRA DE ONCOLOGIA; Medscape; Natera; Onclive; Physicans' Education Resource; Research to Practice; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); GeneCentric (Inst); Gilead Sciences (Inst); Jazz Pharmaceuticals (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; Bristol-Myers Squibb; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics